Rb1 could relieve cognitive deficits by decreasing expressions of IL-1β, Aβ, and glial fibrillary acidic protein (GFAP) and alter the amyloidogenic process of APP into the nonamyloidogenic process in AD rats by exerting anti-inflammatory [128]. Here, APP is linked to Alzheimer disease.